132 related articles for article (PubMed ID: 22574550)
21. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
[TBL] [Abstract][Full Text] [Related]
22. Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response.
Gupta A; Srivastava S; Prasad R; Natu SM; Mittal B; Negi MP; Srivastava AN
Respirology; 2010 Feb; 15(2):349-56. PubMed ID: 20199646
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer.
De Vita F; Orditura M; Auriemma A; Infusino S; Roscigno A; Catalano G
Oncol Rep; 1998; 5(3):649-52. PubMed ID: 9538169
[TBL] [Abstract][Full Text] [Related]
24. Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.
Qian Q; Zhan P; Yu L; Shi Y; Cheng J; Wei S; Wang Q; Song Y
Clin Lung Cancer; 2011 Mar; 12(2):131-7. PubMed ID: 21550560
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
26. Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer.
Wilop S; Crysandt M; Bendel M; Mahnken AH; Osieka R; Jost E
Onkologie; 2008 Dec; 31(12):665-70. PubMed ID: 19060504
[TBL] [Abstract][Full Text] [Related]
27. C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
Patil NS; Zou W; Mocci S; Sandler A; Ballinger M; Flynn S; Kowanetz M; Hegde PS
PLoS One; 2021; 16(2):e0246486. PubMed ID: 33534859
[TBL] [Abstract][Full Text] [Related]
28. The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy.
Jiang AG; Lu HY
J Chemother; 2015 Feb; 27(1):35-9. PubMed ID: 24716851
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study.
Arrieta O; Villarreal-Garza C; Martínez-Barrera L; Morales M; Dorantes-Gallareta Y; Peña-Curiel O; Contreras-Reyes S; Macedo-Pérez EO; Alatorre-Alexander J
BMC Cancer; 2013 May; 13():254. PubMed ID: 23697613
[TBL] [Abstract][Full Text] [Related]
30. Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer.
Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
Eur Respir J; 2010 Oct; 36(4):885-92. PubMed ID: 20185420
[TBL] [Abstract][Full Text] [Related]
31. The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer.
Akerley WL; Nelson RE; Cowie RH; Spinella DG; Hornberger J
Curr Med Res Opin; 2013 May; 29(5):517-25. PubMed ID: 23452275
[TBL] [Abstract][Full Text] [Related]
32. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.
Tas F; Duranyildiz D; Argon A; Oğuz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2005; 22(4):353-8. PubMed ID: 16260852
[TBL] [Abstract][Full Text] [Related]
33. Changes of serum albumin level and systemic inflammatory response in inoperable non-small cell lung cancer patients after chemotherapy.
Wang X; Han H; Duan Q; Khan U; Hu Y; Yao X
J Cancer Res Ther; 2014; 10(4):1019-23. PubMed ID: 25579547
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy.
Naumnik W; Nilklińska W; Ossolińska M; Chyczewska E
Folia Histochem Cytobiol; 2009; 47(4):703-9. PubMed ID: 20430742
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed.
Fiala O; Hosek P; Pesek M; Finek J; Racek J; Buchler T; Poprach A; Hejduk K; Chloupkova R; Sorejs O; Ecksteinova M; Vitovec M; Cizkova K; Kucera R; Topolcan O
Neoplasma; 2017; 64(4):605-610. PubMed ID: 28485168
[TBL] [Abstract][Full Text] [Related]
36. Can Inflammatory and Nutritional Serum Markers Predict Chemotherapy Outcomes and Survival in Advanced Stage Nonsmall Cell Lung Cancer Patients?
Cehreli R; Yavuzsen T; Ates H; Akman T; Ellidokuz H; Oztop I
Biomed Res Int; 2019; 2019():1648072. PubMed ID: 30941358
[No Abstract] [Full Text] [Related]
37. Circulating endothelial cells and microparticles for prediction of tumor progression and outcomes in advanced non-small cell lung cancer.
Najjar F; Alammar M; Al-Massarani G; Almalla N; Aljapawe A; Ikhtiar A
Cancer Biomark; 2017 Sep; 20(3):333-343. PubMed ID: 28800312
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer.
Imai H; Kaira K; Mori K; Ono A; Akamatsu H; Matsumoto S; Taira T; Kenmotsu H; Harada H; Naito T; Murakami H; Endo M; Nakajima T; Yamada M; Takahashi T
BMC Cancer; 2015 Dec; 15():989. PubMed ID: 26690494
[TBL] [Abstract][Full Text] [Related]
39. A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.
Li BT; Drilon A; Johnson ML; Hsu M; Sima CS; McGinn C; Sugita H; Kris MG; Azzoli CG
Ann Oncol; 2016 Jan; 27(1):154-9. PubMed ID: 26487589
[TBL] [Abstract][Full Text] [Related]
40. Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer.
Wang Q; Li X; Ren S; Cheng N; Zhao M; Zhang Y; Li J; Cai W; Zhao C; Cao W; Zhou C
PLoS One; 2015; 10(4):e0122792. PubMed ID: 25860145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]